Schizophrenia Clinical Trials in Atlanta, GA

About Schizophrenia Clinical Trials in Atlanta

Schizophrenia is a chronic brain disorder affecting approximately 2.8 million US adults, characterized by hallucinations, delusions, disorganized thinking, and cognitive difficulties. While current treatments rely primarily on first- and second-generation antipsychotics (risperidone, olanzapine, clozapine), many patients experience incomplete symptom relief or significant side effects. Clinical trials are testing novel mechanisms including muscarinic receptor agonists (like KarXT/xanomeline-trospium), trace amine-associated receptor 1 (TAAR1) agonists, glutamate modulators, and long-acting injectable formulations. Treatment-resistant schizophrenia remains a major focus area, with trials seeking patients who have not adequately responded to standard antipsychotic therapy.

There are currently 14 schizophrenia clinical trials recruiting participants in Atlanta, GA. These studies are seeking a combined 3,584 participants. Research is being sponsored by Reviva Pharmaceuticals, Newron Pharmaceuticals SPA, Karuna Therapeutics, Inc., a Bristol Myers Squibb company and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.